Laboratory of Genome Integrity

Group leader

          Jiří Bártek M.D., Ph.D.

Deputy group leader

          Martin Mistrik Ph.D.

Research associate

          Pavel Moudrý Ph.D.

 

Research

Research in the LIG focuses on various mechanistic aspects of the DNA damage response and DNA repair pathways. Both pathways play a key role in the onset and progress of cancer and thus represent ideal targets for novel anti-cancer drugs.

In addition we endeavor to understand how elevated replication stress in rapidly growing pre-cancerous and cancerous cells affects the progression of the disease. We would also like to understand in detail how the cell copes with replication stress at the molecular level.

Our long term goal is to set up specific DDR response based high throughput screens capable of assessing the effect of different compounds and environmental conditions on DNA integrity in human cells.

In our research we employ state-of-the-art equipment including the Carl Zeiss Super resolution and Spinning Disc microscopic systems.

 

Publications

KUMAR, A., M. MAZZANTI, M. MISTRIK, M. KOSAR, GV. BEZNOUSSENKO, AA. MIRONOV, M. GARRE, D. PARAZZOLI, GV. SHIVASHANKAR, G. SCITA, J. BARTEK a M. FOIANI. ATR Mediates a Checkpoint at the Nuclear Envelope in Response to Mechanical Stress. Cell. 2014, 158(3), 633-646. ISSN 0092-8674.

YAMADA, M., K. WATANABE, M. MISTRÍK, E. VESELÁ, I. PROTIVÁNKOVÁ, N. MAILAND, M. LEE, H. MASAI, J. LUKAS a J. BARTEK. ATR-Chk1-APC/CCdh1-dependent stabilization of Cdc7-ASK (Dbf4) kinase is required for DNA lesion bypass under replication stress. Genes & Development. 2013, 27(22), 2459-2472. ISSN 0890-9369.

BURRELL, R. A., N. MCGRANAHAN, J. BARTEK a C. SWANTON. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013, 501(7467), 338-345. ISSN 0028-0836.

OPLUSTILOVA, L., K. WOLANIN, M. MISTRIK, G. KORINKOVA, D. SIMKOVA, J. BOUCHAL, R. LENOBEL, J. BARTKOVA, A. LAU, MJ. O´CONNOR, J. LUKAS a J. BARTEK. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle. 2012, 11(20), 3837-3805. ISSN 1538-4101.